The Virtual Clinical Trials (VCT) market has surged to an estimated USD 2.64 billion in 2023, projected to reach USD 7.11 billion by 2029, exhibiting a CAGR of 17.95%. North America leads the global market due to advancements in digitalization, telemedicine adoption, and technology integration in healthcare.

Market Trends

•Improving Women’s Health Research: VCTs are addressing barriers to participation in women’s health clinical studies by providing decentralized access, allowing for increased inclusion and diversity.
•Integration of Advanced Technology: Remote patient enrollment, electronic patient-reported outcomes, wearable devices, and sensor technology are enhancing data collection and monitoring.
•Bring-Your-Own-Device Strategy: VCTs adopt the Bring-Your-Own-Device strategy, where participants use personal devices to provide study data, offering convenience and flexibility.

Drivers

•Technological Advancements: Innovations in telemedicine, eHealth platforms, and AI technologies are facilitating efficient data management and patient engagement.
•Rising Healthcare Costs and Regulatory Complexity: VCTs provide cost-effective and streamlined alternatives to traditional trials, reducing expenses and regulatory hurdles.
•Increasing Patient Convenience: VCTs offer greater flexibility, reduced travel burdens, and remote data collection, enhancing patient satisfaction and participation.

Market Challenges

•Data Security and Privacy Concerns: Ensuring the confidentiality and security of sensitive patient data is crucial for VCTs to gain widespread acceptance.
•Lack of Standardized Regulatory Guidance: Regulatory frameworks for VCTs vary across jurisdictions, requiring harmonization to ensure consistency and transparency.
•Ethical Considerations: Addressing ethical implications, such as informed consent and potential coercion, is essential for the ethical conduct of VCTs.

Source link: http://www.businesswire.com/news/home/20240920364706/en/Virtual-Clinical-Trials-Market-Focused-Insights-2024-2029-Featuring-Key-Vendor-Profiles-for-Dassault-Systemes-Medable-Science-37-Thread-Castor-Clinical-Ink-IQVIA-and-Icon—ResearchAndMarkets.com

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.